Trent, D. W., et al., “Genetic variation and microevolution of dengue 2 virus in Southeast Asia.”, Virology, (1989 Oct.) 172(2): 523-35.* |
Rico-Hesse, R., et al., “Molecular evolution of dengue type 2 virus in Thailand.”, American Journal of Tropical Medicine and Hygiene, (1998 Jan.) 58(1):96-101.* |
Holmes, E. C. and S. S. Burch, “The causes and consequences of genetic variation in dengue virus.”, Trends in Microbiology, (2000 Feb.) 8(2):74-7.* |
Harrison, V. R., et al., “Virulence and immunogenicity of a temperature-sensitive dengue-2 virus in lower primates.”, Infection and Immunity, (1977 Oct.) 18(1):151-6.* |
Kinney, R. M., et al., “Construction of infectious cDNA clones for dengue 2 virus:strain 16681 and its attenuated vaccine derivative, strain PDK-53.”, Virology, (Apr. 14, 1997) 230(2):300-8.* |
PCT International Search Report from international application PCT/US00/08199 (corresponding to 09/535,117), dated Oct. 23, 2000 (9 pages). |
Jirakanjanakit et al., “The use of Toxorhynchites splendens for identification and quantitation of serotypes contained in the tetravalent live attenuated dengue vaccine”, Vaccine, GB Butterworth Scientific. Guildford, vol. 17, No. 6, Feb. 1999, pp. 597-601. |
Hoke et al., “Preparation of an attenuated Dengue 4 virus vaccine II safety and immunogenicity in humans”, American J. of Tropical Medicine & Hygiene, Lawrence, KS, US, vol. 43, No. 2, Aug. 1990, pp. 219-226. |
D. J. Gubler, “The global pandemic of dengue/dengue haemorrhagic fever: Current status and prospects for the future”, Annals Academy of Medicine Singapore, vol. 27, No. 2, Mar. 1998, pp. 227-234. |
Putnak et al., “Development of a purified, inactivated, dengue-2 virus vaccine prototype in vero cells: immunogenicity and protection in mice and rhesus monkeys”, J. of Infectious Diseases, vol. 174, No. 6, 1996, pp. 1176-1184. |
Puri Beena et al., “Molecular analysis of dengue virus attenuation after serial passage in primary dog kidney cells”, J. of General Virology, vol. 78, No. 9, 1997, pp. 2287-2291. |
Marchette et al., “Preparation of an attenuated dengue 4 virus vaccine I pre-clinical studies”, American J. of Tropical medicine & Hygiene, Lawrence, KS, US, vol. 43, No. 2, Aug. 1990, pp. 212-218. |
Bhamarapravati et al., “Live attenuated tetravalent dengue vaccine”, Vaccine, GB Butterworth Scientific Guildford, vol. 18, Mar. 2000, pp. 44-47. |
Botstein and Shortle, 1985, “Strategies and applications of in vitro mutagenesis”, Science, vol. 229, No. 4719, pp. 1193-1201. |
Clarke and Casals, 1958, “Techniques for hemagglutination and hemagglutination-inhibition with arthropod-borne viruses”, Am. J. Trop. Med. Hyg., 7, 561-573. |
Halstead et al., 1984, “Selection of attenuated Dengue 4 viruses by serial passage in primary kidney cells,” Am J. Trop. Med. Hyg, 33(4), pp. 654-665, 666-671, 672-678, 679-683. |
Hayflick, 1988, “History of cell substrates used for human biologicals”, Symposium on Continuous Cell Lines as Substrates for Biologicals, Arlington, Virginia, USA, pp. 11-26. |
Hoke et al., 1990, “Preparation of an attenuated Dengue 4 virus vaccine”, Am J. Top. Med. Hyg., 43(2), pp. 219-226. |
Marchette, 1990, “Preparation of an attenuated Dengue 4 virus vaccine”, Am J. Top. Med. Hyg., 43(2), pp. 212-218. |
Mizrahi, ed., Viral Vaccines, “WHO Attitude to Viral Vaccines”, Wiley-Liss, New York (1990), pp. 39-60. |
Putnak et al, 1996, “Development of a purified inactivated, Dengue-2 virus vaccine prototype in vero cells: immunogenecity and protection in mice nad Rhesus monkeys,” J. Infectious Dis., 174, pp.1176-1184. |
Russell, et al., “A plaque reduction test for dengue virus neutralizing antibodies”, J. Immunology, vol. 99, No. 2, 1967, pp.285-290. |
Scott, 1983, “Dengue 2 vaccine: Dose response in volunteers in relation to yellow fever immune status,” J. Infectious Diseases, vol., 148, No. 6, pp.1055-1060. |
Sukhavachana et al, 1966, “Tissue culture techniques for the study of dengue viruses”, Abreges des Communications, Bull. WHO 35, pp. 65-66. |
Deller and Smith, 1984, Laboratory Methods, “Oligonucleotide-directed mutagenesis: a simple method using two oligonucleotide primers and a single-stranded DNA template”, DNA, vol. 3, No. 6, pp.479-488. |
Bhamarapravati, 1987, “Immunization with a live attenuated dengue-2-virus candidate vaccine: clinical, immunological and biological responses in adult volunteers”, Bull. WHO, 65(2), pp.189-195. |
Conrad et al., “Infection with Nippostrongylus Brasiliensis or injection of anti-IgD antibodies markedly enhances Fc-receptor-mediated interleukin 4 production by non-B, non-T cells”, J. Exp. Med., vol. 171, pp.1497-1508. |
Dharakul, et al., “Dengue virus-specific memory T cell responses in human volunteers receiving a live attenuated dengue virus Type 2 candidate vaccine”, J. Infect. Dis., vol. 170, pp. 27-33. |
Edelman et al., “A live attenuated Dengue-1 vaccine candidate passaged in primary dog kidney cell culture is attenuated and immunogenic for humans”, 1994, Am. J. Trop. Med. Hyg., 170, pp. 1448-1455. |
Halstead, 1978, “Studies on the attenuation of Dengue 4”, Asian J. Infectious Dis., vol. 2, pp. 112-117. |
Halstead, 1970, “Long ‘cure’ improves results of pig heterograft heart valves”, JAMA, vol. 211, No. 6, pp. 911-916. |
Johnson and Roehrig, “New mouse model for Dengue virus vaccien testing”, J. Virology, Jan. 1999, vol. 73, No. 1, pp. 783-786. |
Kontny et al., “Gamma interferon augments Fcy receptor-mediated Dengue virus infection of human monocytic cells”, J. Virology, Nov. 1988, vol. 62, No. 11, pp. 3928-3933. |
Kurane et al., “Dengue virus-specific human T cell clones”,J. Exp. Med., vol. 170, 1989, pp. 763-775. |
Kurane et al., “Activation of T lymphocytes in dengue virus infections”, J. Clin. Invest., vol. 88, 1991, pp. 1473-1480. |
Kurane et al., “T cell activation in vivo by Dengue virus infection”, J. Clin. Lab. Immunol., 1995, vol. 46, pp.35-40. |
Peters, “Actions of cytokines on the immune response and viral interactions: an overview”, Hepatology, vol. 23, 1996, pp. 909-916. |
Sittisombut et al., “Lack of augmenting effect of interferon-y on Dengue virus multiplication in human peripheral blood monocytes”, J. Medical Virology 45:43-49, 1995. |
Sabin, 1959, “Dengue”, Viral and Rickettsial Infections of Man, Philadelphia: JB Lippincott Company, pp. 361-373. |
Simmons et al., “Experimental Studies of Dengue”, 1931, Manila BUreau of Printing, pp. 1-489. |
Wisseman and Sweet, “Immunological studies with Group B arthropod-borne viruses”, Am. J. Trop. Med. Hyg., vol. 11, pp. 570-575 (1962). |
Yuill et al., “Dengue-virus recovery by direct and delayed plaques in LLC-MK2 cells”, Am. J. Trop. Med. Hyg., Vol 17, 1968, pp. 441-448. |
Edelman, et al., “A Live Attenuated Dengue-1 Vaccine Candidate (45AZ5) Passaged in Primary Dog Kidney Cell Culture SIs Attenuated and Immunogenic for Humans”, J. Infectious Diseases, 1994:170:1448-1455 (Dec.). |
Angsubharkorn et al., “Dengue-3 (16562) PGMK 33 Vaccine: Neurovirulence, Viremia and Immune Responses in Macaca Fascicularis”, Southeast Asian J. Trop. Med. Public Health, vol. 25, No. 3, Sep. 1994. |
(XP-002150293) Sun et al., Program Abstracts from the First Annual Conference on Vaccine Research, May 30-Jun. 1, 1998, “Phase I Study of Two Doses of Monovalent Live-Attenuated Dengue Virus Vaccines” (2 pages). |
Vaughn, et al., “Testing of a dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers”, Vaccine, vol. 14, No. 4, pp. 329-336, 1996. |
Smith and Wright, “Synthesis of Proteins and Glycoproteins in Dengue Type 2 Virus-Infected Vero and Aedes albopictus Cells”, J. Gen. Virol., (1985) 66: 559-571. |
Kraiselburd, E., “Comparative Infectivity Determination of Candidate Live Dengue Virus Vaccine in Monkeys, Mosquitoes and cell cultures”, Annual and Final Report, May 1987, pp. 1-20. |
Osatomi, K., “Complete Nucleotide Sequence of Dengue Type 3 Virus Genome RNA”, Virology 176:643-647 (1990). |
Puri, B., “Molecular analysis of dengue virus attenuation after serial passage in primary dog kidney cells”, J. General Virology (1997) 78:2287-2291. |